gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ALLOHealthcareBiotechnology

Allogene Therapeutics, Inc. Common Stock (ALLO)

$1.19+6.25%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$1.19▲ 7.21% in range
Nov 4, 2025Low $1.05 · High $3.06Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Allogene Therapeutics closed at $1.19 on Nov 4, up 6.25%, 61.1% below its 52-week closing high. Volume of 16.5M shares was 2.01× its 20-day average (well above normal).

Split-adjusted performance: -18.5% over one month, -48.5% over six months, +0.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $4.64M, with a net margin of -919.8%.

Short interest was 53.4M shares at the Oct 15 settlement, down 4.0% from the prior report (19.4% of float, 9.2 days to cover).

Market cap$411.1M345.5M shares
Revenue · quarter$4.6M—
Diluted EPS$-0.13—
P/E · TTM—P/S 88.6×
Net margin-919.8%Gross 100.0%
Dividend yieldNone
52-week range1.05 – 3.06−61.1% from high
Volume16.5M2.01× 20-day avg
Volatility · 60d56.2%Annualised
Short % of float19.4%9.3 days to cover
Net cash$332.6MCash $332.6M
Next earnings—Not scheduled
Split-adjusted performance
1W −8.5%1M −18.5%3M −39.6%6M −48.5%YTD −13.1%1Y +0.8%3Y −56.9%5Y −92.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum28
Revenue growth—
Net margin30
Value (low P/E)—
Size62

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short53.4M−4.0% vs prior
Days to cover9.3Settled Oct 15
% of float19.4%
Short vol. 10d25.7%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ALLOAllogene Therapeutics$1.19+6.25%−48.5%—−919.8%—$411.1M
EDITEditas Medicine$2.72+4.62%−14.3%+232.3%−153.3%—$417.7MCompare
TECXTectonic Therapeutic$20.30+6.95%−30.0%———$396.9MCompare
ZURAZura Bio Limited$4.02+0.75%−17.8%———$387.2MCompare
CCCCC4 Therapeutics$3.12−2.80%+6.5%+2.8%−355.9%—$383.8MCompare
SRZNSurrozen$31.65+5.08%−7.3%+408.6%640.8%—$372.0MCompare
FENCFennec Pharmaceuticals$10.35−3.27%+44.2%+85.2%11.0%—$362.9MCompare
EIKNEikon Therapeutics$6.39+15.14%−35.9%———$346.1MCompare
RGNXREGENXBIO$7.71+1.05%−24.6%+405.7%21.0%—$509.0MCompare

News about Allogene Therapeutics

All news →
Allogene Therapeutics Announces Pricing of Public Offering of Common StockGlobeNewswire Inc. · Apr 15, 2026Neutral

Quick answers

What does Allogene Therapeutics do?
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders.
What is ALLO's market cap?
$411.13M, based on the Nov 4 close of $1.19.
Does Allogene Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ALLO is sold short?
53.4M shares, 19.4% of float, as of Oct 15, 2026.
What sector is ALLO in?
Healthcare, in the Biotechnology industry.

About Allogene Therapeutics

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

HQ: South San Francisco, CA152 employeesListed Oct 11, 2018allogene.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology